Pfizer is a therapy leader in Inflammation & Immunology. Many chronic inflammatory diseases are poorly managed by existing treatments that provide Suboptimal relief¹. Our goal is to transform the treatment landscape by addressing the root cause of inflammation at the molecular level through advanced approaches that target inflammation of the joints and skin by disrupting pathways believed to play a role in inflammation².

We have consistently developed and delivered medicines to help address patients’ needs in rheumatology and medical dermatology. We facilitate patient  awareness and education via our Facebook page All About Arthritis.

We also regularly conduct disease awareness programs for patients, as well as scientific initiatives and partnerships for healthcare professionals including national and international forums (such as INPSIRE), that bring top global experts to discuss latest scientific updates and deliberate on their experiences.

1. Bykerk V. Unmet needs in rheumatoid arthritis. J Rheumatol Suppl. 2009 Jun;82:42-6.
2. Demoruelle MK, Deane KD, Holers VM. When and where does inflammation begin in rheumatoid arthritis?. Curr Opin Rheumatol. 2014;26(1):64-71.
3. Ogdie A, de Vlam K, McInnes IB, et al Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. RMD Open 2020;6:e001042. doi: 10.1136/rmdopen-2019-001042

This information—including product information—is intended only for residents of India. The products discussed herein may have different labelling in different countries. Patients should always ask their doctors for medical advice.